---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-016014"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2025-06-23T23:59:59+00:00"
generated_at: "2026-05-18T23:36:22.727687+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lipocine to host R&D event July 9, 2025 on LPCN 1154 for postpartum depression; Phase 3 data Q2 2026

## Summary
- Virtual R&D investor event on July 9, 2025 at 11 AM ET to discuss LPCN 1154 (BRLIZIO) for postpartum depression (PPD).
- Phase 3 registrational study recently initiated; top-line data expected in Q2 2026.
- Event features Dr. Kristina Deligiannidis; includes clinical, regulatory, and development updates with Q&A.
- LPCN 1154 is an oral brexanolone formulation targeting rapid symptom relief with 48-hour outpatient treatment.

## SEC filing metadata
- accession: 0001641172-25-016014
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2025-06-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000164117225016014/0001641172-25-016014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000164117225016014/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-016014
- JSON: https://secwatch.observer/filing/0001641172-25-016014.json
- Plain text: https://secwatch.observer/filing/0001641172-25-016014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.